Hello! Welcome to Win-Win Chemical
english English    english 中文

Win-Win Fine Chemical Expert Heath Chemicals

Email: sales@win-winchemical.com

Hotline :0086-0577-64498589

CPhI & P-MEC China 2022 Postponement Notice
win-win Industry news
Sponsored by Informa Markets, China Chamber of Commerce for Import and Export of Medicines and Health Products, and co-organized by Shanghai Bohua International Exhibition Co., Ltd. The 21st world pharmaceutical raw materials China Exhibition and the 16th world pharmaceutical machinery, packaging equipment and materials China exhibition, originally scheduled to be held in Shanghai New International Expo Center from June 21 to 23, 2022, will be postponed, and the specific time will be notified.
Read More...
The first batch of Pfizer's new crown special drug PAXLOVID in China began to be used for treatment
win-win Industry news
On March 23, the National Health and Medical Commission issued the "Notice on Adjusting Indications of Anti-New Coronavirus Drug PF-07321332/Ritonavir Tablets (Paxlovid), etc." Ordinary type and adults with high risk factors for progression to severe disease", delete "Adolescents aged 12-17 years weighing more than 40 kg". PAXLOVID is a combination drug developed by Pfizer. Nematevir is a protease inhibitor that blocks the protease activity necessary for coronavirus replication. Ritonavir, on the other hand, is used to slow down the metabolism or breakdown of nematevir, allowing it to remain active in the body for longer at higher concentrations, which together affect the reproduction of the virus. According to Pfizer's previously published clinical trial data, compared with the placebo group, patients treated with PAXLOVID within 3 days and 5 days after symptom onset had an 89% and 88% reduction in hospitalization or mortality, respectively, and viral load The amount has been reduced by a factor of 10. In the overall 28-day study population, no deaths were reported in patients receiving the drug, compared with 10 (1.6%) deaths in patients receiving placebo.
Read More...
AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
win-win Industry news
AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved the oral JAK1 inhibitor Rinvoq (Rinvoq, generic name: upadacitinib, upadacitinib extended-release tablets) for the treatment of adults and adults aged 12 and Refractory, moderate to severe atopic dermatitis (AD) in the above children and adolescents. This approval marks the first indication that Rinvoq has been approved in China. Rinvoq is specifically indicated for: children and adolescents (≥12 years) and adults with refractory, moderate-to-severe atopic dermatitis (AD) who have not responded well to or are not suitable for other systemic therapy (eg, hormones or biologics) patient. In terms of medication, for children, adolescents and adults with a body weight of ≥ 40 kg and an age of ≥ 12 years, the starting dose is 15 mg once a day. The dose can be increased to 30 mg once daily in children and adolescents and adults under 65 years of age who are unresponsive. So far, Rinvoq has been approved in the EU for 4 indications (rheumatoid arthritis [RA], psoriatic arthritis [PsA], ankylosing spondylitis [AS], atopic dermatitis [AD]), in 3 indications (RA, PsA, AD) have been approved in the United States. Rinvoq 15mg dose is suitable for the treatment of all the above indications, while Rinvoq 30mg is only suitable for the treatment of AD.
Read More...
Sinovac and Antaiwei cooperate to develop oral anti-coronavirus drugs
win-win Industry news
On February 20, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as Kexing Pharmaceuticals) issued an announcement that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Pharmaceuticals, would On February 18, Antaiwei signed the "SHEN26 Project Cooperation Agreement" (hereinafter referred to as the "Cooperation Agreement") with Shenzhen Antaiwei Biomedical Co., Ltd. (hereinafter referred to as "Antaiwei"). The intellectual property rights of SHEN26 are exclusively licensed to Shenzhen Kexing, and the subsequent research and development rights and commercialization rights of the products are transferred to Shenzhen Kexing. The signing of this cooperation agreement will further accelerate the company's innovative drug layout, increase product reserves, enhance the company's core competitiveness, enrich the company's anti-viral product pipeline, and continuously improve the pharmaceutical research and development, production and sales systems, and promote the company's business continuity, rapidity and health. developing.
Read More...
Singapore develops first domestically produced oral drug for novel coronavirus
win-win Industry news
On January 14, the Experimental Drug Research and Development Center under the Agency for Science, Technology and Research (A*STAR) of Singapore recently developed a 3CL protease inhibitor, which will be used in the development of oral drugs for the new coronavirus in Singapore. In 2019, A*STAR established the Singapore Experimental Drug Research and Development Centre (EDDC) to strengthen the biomedical field in Singapore. Recently, the Experimental Drug Research and Development Center has successfully developed a 3CL protease inhibitor. The main protease in the new coronavirus is 3CL protease, and 3CL protease inhibitors prevent the virus from self-replication by inhibiting the expression of 3CL protease. This time, Singapore has developed a technology that can inhibit this protein, which is very effective against the new coronavirus and its variant strains. This is also the key technology used in Pfizer's new coronavirus oral medicine. On the 14th, China Genting Xinyao and Singapore's Experimental Drug Research and Development Center announced that they had reached a global license agreement to jointly develop and produce oral drugs for the new coronavirus. It is reported that the clinical trial plan of this new coronavirus oral drug will start in the second half of this year.
Read More...
CPHI China & P-MEC China 2021 extension announcement
win-win Industry news
Novel coronavirus pneumonia epidemic prevention and control situation is becoming more and more severe in recent years. In order to strictly implement the joint defense joint control mechanism of the State Council, in order to effectively protect the safety and health of participants, based on feedback from exhibitors, spectators and cooperative agencies, China has made many rounds of consultation and careful consideration. Shanghai Bohua International Exhibition Co., Ltd. has decided that the 21st world pharmaceutical raw materials China Exhibition and the 16th world pharmaceutical machinery, packaging equipment and materials China exhibition originally scheduled to be held from December 16 to 18, 2021 will be postponed to June 21-23, 2022, and the venue of the exhibition will remain unchanged (still Shanghai New International Expo Center). Although the offline exhibition has been postponed, the "VEC online exhibition" (VEC. Pharmasources. Com) of CPHI & p-mec China Exhibition held from November 18, 2021 to January 18, 2022 will continue as usual, continue to help exhibitors connect global buyers and play the role of brand exhibition exchange and cooperation platform. See you CPHI 2022!
Read More...
Page:1/ Total:5 First  Prev  Next  Last